Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.

Journal of thrombosis and haemostasis : JTH - 1 Aug 2012

Kuether E L, Schroeder J A, Fahs S A, Cooley B C, Chen Y, Montgomery R R, Wilcox D A, Shi Q

Abstract excerpt

BACKGROUND: The development of inhibitory antibodies, referred to as inhibitors, against exogenous factor VIII in a significant subset of patients with hemophilia A remains a persistent challenge to the efficacy of protein replacement therapy. Our previous studies using the transgenic approach pr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantibodies
Share to Blood Platelets
Share to Bone Marrow Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Hemophilia A

Share to Lentivirus

Share to Mice, 129 Strain

Share to Transduction, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 22632092
DOI: 10.1111/j.1538-7836.2012.04791.x
PMCID: PMC3419807

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22632092-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.PMID 22632092Read ↗

The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.Semantic proximity Read ↗

Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.Semantic proximity Read ↗

In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.Semantic proximity Read ↗

Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.Semantic proximity Read ↗

Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.Semantic proximity Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Hematopoietic Stem Cells Encoding Porcine Factor VIII Induce Pro-coagulant Activity in Hemophilia A Mice with Pre-existing Factor VIII ImmunitySemantic proximity Read ↗

Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.Semantic proximity Read ↗

Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.Semantic proximity Read ↗

Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.Semantic proximity Read ↗

Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.Semantic proximity Read ↗

Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.